BRAF/MEK Inhibitors

Research by Fillmore and his collaborators evaluates the real-world effectiveness of BRAF and MEK inhibitors compared to immune checkpoint inhibitors in patients with cutaneous melanoma. This work provides critical data on clinical outcomes within the veteran population, offering insights into the comparative efficacy of targeted therapies versus immunotherapy in a practical clinical setting.